

## ASX ANNOUNCEMENT

ASX: 1AI | 18 May 2026

### Algorae Expands AI Drug Combination Pipeline with Multi-Anchor AOS2 Program

#### Highlights

- Multi-anchor program extends AOS2 from a single anchor (CBD) to 18 anchor drugs, broadening Algorae's pipeline of AI-predicted combination opportunities
- AOS2 generated over 9 million in silico synergy predictions across drug–drug–cell line combinations spanning diverse therapeutic areas and mechanisms of action
- Preliminary filtering identified over 478,000 synergy predictions with more than 6,000 combinations with predicted synergy and biological generalisability
- Four synergy metrics (ZIP, Bliss, HSA, Loewe) combined with model confidence weighting enable prioritisation of the strongest candidates
- Structured curation underway to produce a high-priority shortlist for further evaluation, factoring in commercial and intellectual property considerations
- Shortlisted candidates expected to inform Algorae's engagement with the Peter MacCallum Cancer Centre ("PMCC") on independent validation and the previously announced second program, which is now underway

AI-enabled pharmaceutical company **Algorae Pharmaceuticals Ltd (ASX: 1AI)** ("Algorae" or "the Company") is pleased to report it has completed the prediction-generation phase of a multi-anchor drug combination program, with AlgoraeOS v2 ("AOS2") producing in silico synergy predictions across 18 anchor drugs.

Following the successful generation of synergy predictions for cannabidiol, Algorae's first single-anchor program using AOS2 (refer ASX announcement dated 12 December 2025), the Company scaled the platform's application to 18 anchor drugs. The multi-anchor program was designed to leverage the scale and efficiency of AOS2 to provide Algorae with a more diversified pipeline of AI-predicted combination opportunities.

The prediction set evaluates 18 anchor drugs in combination with thousands of approved and investigational compounds across a panel of human cell lines, representing over **9 million potential drug–drug–cell line combinations**. The 18 anchors were selected to span a diverse range of therapeutic areas and mechanisms of action, providing the Company with broad optionality across multiple disease contexts.

Each prediction in the dataset includes the four well-recognised synergy metrics (**ZIP, Bliss, HSA and Loewe**) alongside confidence-weighted measures of predictive uncertainty. Together, these outputs enable rigorous, risk-aware prioritisation across the full prediction set and underpin the Company's structured approach to candidate selection.

### Initial filtering and prioritisation

Algorae has commenced a structured analysis of the multi-anchor prediction set, applying prioritisation thresholds informed by, and refined from, the methodology successfully applied to the CBD prediction set. These thresholds balance the magnitude of predicted synergy with uncertainty reduction and biological generalisability across multiple cell lines. These thresholds were informed by, and refined from, the methodology applied to the CBD prediction set (refer ASX announcement dated 12 December 2025).

AOS2 evaluated over **9 million potential drug–drug–cell line combinations** across the 18 anchor drugs. From this prediction set, initial filtering has identified:

- more than **478,000 individual synergy predictions** passing preliminary synergy and uncertainty thresholds;
- over **6,000 drug combinations** demonstrating predicted synergy across multiple cell lines, indicating greater biological robustness.

Given the larger scale and greater diversity of the multi-anchor program, the next phase of curation will incorporate anchor-specific considerations and apply additional filters reflecting:

- the predicted strength and consistency of synergy;
- biological robustness across cell lines;
- the novelty of each combination relative to existing empirical data; and
- commercial and intellectual property relevance.

Chief Scientific Officer, **Dr James McKenna**, commented:

*“This program provides a compelling demonstration of the in silico predictive capability of AOS through the rapid generation of large-scale predictions across approved and investigational drugs with diverse mechanisms of action. In doing so, the program has dramatically expanded the Company's pool of candidate drug combinations for further evaluation, while reducing reliance on traditional, resource-intensive screening methods.”*

### Implications and next steps

The curation of the multi-anchor prediction set will incorporate commercial and intellectual property considerations alongside the technical prioritisation criteria, producing a shortlist of candidates for potential progression into preclinical validation. The Company will update shareholders once the shortlist has been finalised.

The shortlisted candidates are expected to inform the Company's ongoing discussions with **Peter MacCallum Cancer Centre** (“PMCC”) regarding independent validation and the previously announced second program, which is now underway. This work builds on the independent preclinical validation of AlgoraeOS v1 (AOS1) at PMCC (refer ASX announcement dated 5 December 2025) and the CBD multi-combination prediction set (refer ASX announcement dated 12 December 2025).

In parallel with the Company's AI drug discovery activities, the commercial pharmaceutical business continues to progress, with additional products and agreements progressing through the pipeline. Algorae will continue to update shareholders as key commercial and scientific milestones are achieved.

**Authorised for release by the Board of Directors of Algorae Pharmaceuticals Ltd**

**END.**

### **Corporate and Media Enquiries**

Mr David Hainsworth

Executive Chairman

E: [investors@algoraepharma.com](mailto:investors@algoraepharma.com)

### **About Algorae Pharmaceuticals**

Algorae Pharmaceuticals (ASX: 1AI) is an AI-enabled pharmaceutical company with a dual focus on drug-combination discovery and pharmaceutical commercialisation. The Company's proprietary AI platform, AlgoraeOS, applies machine learning and deep neural networks to identify synergistic drug combinations and guide dose selection for preclinical development. In parallel, Algorae operates a commercialisation business, AlgoraeRx, that sources, licenses and supplies generic and specialty medicines in Australia and New Zealand through partnered manufacturers and established distribution channels. Algorae collaborates with leading research institutions and industry partners to translate AI-predicted therapies and to expand patient access to high-quality medicines.

Algorae is listed and publicly traded on the Australian Securities Exchange (ASX: 1AI), providing investors an opportunity to participate in the Company's growth.

For more information visit [www.algoraepharma.com](http://www.algoraepharma.com) or follow @algoraepharma on X or LinkedIn.

### **Forward-looking Statements**

This document may contain certain forward-looking statements, relating to Algorae's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Algorae is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.